BSX Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of 12.41% compared to Boston Scientific's net margin of 28.41%. Boston Scientific's return on equity of 8.96% beat Intuitive Surgical's return on equity of 15.6%.

Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 16.91%. On the other hand Intuitive Surgical has an analysts' consensus of $630.35 which suggests that it could grow by 28.96%. Given that Intuitive Surgical has higher upside potential than Boston Scientific, analysts believe Intuitive Surgical is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.616%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.6B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Boston Scientific's net income of $566M is lower than Intuitive Surgical's net income of $685.7M. Notably, Boston Scientific's price-to-earnings ratio is 79.12x while Intuitive Surgical's PE ratio is 76.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.78x versus 21.19x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 12.41% compared to Boston Scientific's net margin of 16.85%. Boston Scientific's return on equity of 8.96% beat Insulet's return on equity of 43.11%.

Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 16.91%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 20.04%. Given that Insulet has higher upside potential than Boston Scientific, analysts believe Insulet is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.6B, which are larger than Insulet quarterly revenues of $597.5M. Boston Scientific's net income of $566M is higher than Insulet's net income of $100.7M. Notably, Boston Scientific's price-to-earnings ratio is 79.12x while Insulet's PE ratio is 45.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.78x versus 9.33x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 12.41% compared to Boston Scientific's net margin of 26.88%. Boston Scientific's return on equity of 8.96% beat ResMed's return on equity of 25.56%.

Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 16.91%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 19.86%. Given that ResMed has higher upside potential than Boston Scientific, analysts believe ResMed is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.92% to investors and pays a quarterly dividend of $0.53 per share. Boston Scientific pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.6B, which are larger than ResMed quarterly revenues of $1.3B. Boston Scientific's net income of $566M is higher than ResMed's net income of $344.6M. Notably, Boston Scientific's price-to-earnings ratio is 79.12x while ResMed's PE ratio is 26.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.78x versus 6.73x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 12.41% compared to Boston Scientific's net margin of 8.48%. Boston Scientific's return on equity of 8.96% beat Stryker's return on equity of 15.22%.

Boston Scientific has a consensus price target of $115.62, signalling upside risk potential of 16.91%. On the other hand Stryker has an analysts' consensus of $424.43 which suggests that it could grow by 13.64%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Boston Scientific has a beta of 0.772, which suggesting that the stock is 22.845% less volatile than S&P 500. In comparison Stryker has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.393%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.6B, which are smaller than Stryker quarterly revenues of $6.4B. Boston Scientific's net income of $566M is higher than Stryker's net income of $546M. Notably, Boston Scientific's price-to-earnings ratio is 79.12x while Stryker's PE ratio is 48.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.78x versus 6.37x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.